SCHEMBL6493101

SCHEMBL6493101

CC(C)(C)[Si](C)(C)OCCn1ccc(C(=O)N2CCN(c3cccc(C(N)=O)c3)CC2)c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP14 Q460N5 2/20 0.41
PARP10 Q53GL7 2/20 0.41
TSHR P16473 5/20 0.39
LMNA P02545 4/20 0.39
USP2 O75604 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
THRB P10828 1/20 0.38
FAAH O00519 3/20 0.38
DRD3 P35462 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494220 0.88 CHRM4 (0.42) TSHRLMNATHRBDRD3NPSR1
SCHEMBL5763806 0.86 ALDH1A1 (0.43) TSHRLMNAUSP2MAPTMAPK1
SCHEMBL6495942 0.84 PARP14 (0.41) PARP14PARP10TSHRLMNAUSP2
SCHEMBL6502509 0.83 USP2 (0.47) PARP14PARP10TSHRLMNAUSP2
SCHEMBL6493098 0.81 PARP14 (0.42) PARP14PARP10TSHRLMNAUSP2
SCHEMBL1382879 0.79 PARP14 (0.52) PARP14PARP10TSHRLMNAUSP2
SCHEMBL1382320 0.74 TSHR (0.47) PARP14PARP10TSHRLMNAUSP2
SCHEMBL5763267 0.73 PARP14 (0.41) PARP14PARP10TSHRLMNAUSP2
SCHEMBL6506210 0.72 CHRM4 (0.42) TSHRLMNADRD3NPSR1TP53
SCHEMBL1383519 0.70 TSHR (0.50) PARP14PARP10TSHRLMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC PARP14 951/4885PARP10 789/4885TSHR 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.